RPRX Insider Trading Activity and SEC Form 4 Filings
Trump's trades in RPRX
From his financial disclosures
-
0 purchases
$2K+
2 sales
Sale
Apr 7, 2026
Reported 85d later
$1K - $15K
Sale
Feb 19, 2026
Reported 84d later
$1K - $15K
Many orders in these accounts are placed by the account manager.
RPRX insider trading summary
Over the past 12 months, insiders at Royalty Pharma plc (RPRX) reported 63 sales worth $73.9M by 5 insiders and no open-market purchases on SEC Form 4. Net insider selling was $73.9M.
Latest RPRX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 5, 2026 | Marshall Urist | EVP, Research & Investments | Sell | $236K (4,126 @ $57.10) |
| Sep 28, 2026 | Marshall Urist | EVP, Research & Investments | Sell | $239K (4,126 @ $57.88) |
| Sep 22, 2026 | Christopher Hite | EVP & Chairman, Partnering | Sell | $231K (3,927 @ $58.93) |
| Sep 22, 2026 | Christopher Hite | EVP & Chairman, Partnering | Sell | $5.6M (96,073 @ $58.51) |
| Aug 18, 2026 | Christopher Hite | EVP & Chairman, Partnering | Sell | $6.0M (100,000 @ $59.97) |
| Aug 13, 2026 | Terrance P. Coyne | EVP & CFO | Sell | $105K (1,772 @ $59.14) |
| Aug 13, 2026 | Terrance P. Coyne | EVP & CFO | Sell | $541K (9,230 @ $58.59) |
| May 26, 2026 | Terrance P. Coyne | EVP & CFO | Sell | $3.5M (64,399 @ $53.98) |
| May 20, 2026 | Marshall Urist | EVP, Research & Investments | Sell | $722K (13,684 @ $52.75) |
| May 14, 2026 | Gregory Norden | Director | Sell | $161K (3,045 @ $53.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.